Robert E Miller
CIK 1367082 · Chief Financial Officer · last filed 2019-01-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SNOAW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PETALUMA, CA 94954
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOAW) Delisted | Chief Financial Officer | 39,668 | — | — | $86.8K | 12 | 2019-01-15 |
| Sonoma Pharmaceuticals, Inc. (OCLSW) Delisted | Chief Financial Officer | 17,678 | — | — | $0 | 1 | 2016-12-02 |
| Sonoma Pharmaceuticals, Inc. (OCLS.W) Delisted | Chief Financial Officer | — | — | — | $0 | 1 | 2015-08-25 |
| Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Chief Financial Officer | 10,429 | — | — | $21.8K | 11 | 2014-03-06 |
Recent Filings · Page 2 of 3
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-09 | Sonoma Pharmaceuticals, Inc. (SNOAW) Delisted | Buy (P) | +1,000 | $6.9K | EDGAR |
| 2016-12-12 | Sonoma Pharmaceuticals, Inc. (SNOAW) Delisted | Buy (P) | +5,000 | $24.3K | EDGAR |
| 2016-12-02 | Sonoma Pharmaceuticals, Inc. (OCLSW) Delisted | Grant (A) | +15,593 | $0 | EDGAR |
| 2015-08-25 | Sonoma Pharmaceuticals, Inc. (OCLS.W) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-06 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-09-20 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-08-27 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-03-09 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-17 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-04-01 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.